2024-07-01 20:46:33 ET
Summary
- Zimmer Biomet's share price has been under pressure in recent months due to soft growth, poor cash flows, and higher interest rates.
- Demographics, the rise of ASCs and technological advancements should be supportive of long-term growth.
- Zimmer Biomet also expects new product launches to accelerate growth in the second half of 2024.
- While stronger growth and improving margins should support Zimmer's stock, I continue to think that Stryker has a far stronger business.
Zimmer Biomet's ( ZBH ) share price has been under considerable pressure over the past 3 months, potentially due to a combination of soft growth, poor cash flows and higher interest rates. Some of these issues are expected to begin correcting later in the year though....
Read the full article on Seeking Alpha
For further details see:
Zimmer Biomet: Brighter Prospects In H2 2024